Explore

Former NBA Player Jason Collins Diagnosed with Stage 4 Glioblastoma

Former NBA Player Jason Collins Diagnosed with Stage 4 Glioblastoma

Jason Collins, a former NBA player known for his time with the Atlanta Hawks, has been diagnosed with Stage 4 glioblastoma, a highly aggressive form of brain cancer. Collins, who made history as the first openly gay active player in the NBA, shared his diagnosis in an interview with ESPN. He recounted the initial signs of his illness, which included difficulty focusing and memory loss, leading to a CT scan at UCLA hospital. The diagnosis was confirmed after a series of tests and a biopsy. Collins expressed his determination to fight the disease, drawing inspiration from his grandmother, who battled Stage 4 stomach cancer.

Gene-Edited T-Cell Therapy Shows Promise for Incurable Leukemia Patients

Gene-Edited T-Cell Therapy Shows Promise for Incurable Leukemia Patients

A new form of immune therapy using gene-edited T-cells from healthy donors has shown promising results in driving an otherwise incurable form of T-cell leukemia into remission. This innovative treatment involves re-engineering T-cells to recognize and attack leukemia cells, offering a potential lifeline for patients whose cancer has resisted standard treatments. Unlike personalized therapies, these T-cells can be prepared in advance as an 'off-the-shelf' product, allowing for rapid administration to patients in urgent need. The therapy has been tested on a small group of patients, with some achieving deep remissions, paving the way for subsequent stem cell or bone marrow transplants, which are currently the only realistic routes to long-term cures.

Curebound Awards $8.5 Million for Cancer Research, Supporting 23 New Studies

Curebound Awards $8.5 Million for Cancer Research, Supporting 23 New Studies

Curebound, a philanthropic organization dedicated to cancer research, has announced the allocation of $8.5 million in grants to support 23 new cancer research projects. This funding includes a $1 million Cure Prize aimed at advancing groundbreaking cancer research with near-term clinical applications. The grants are distributed across various programs such as Catalyst, Discovery, Equity, Targeted Grants, and the Cure Prize, focusing on key research areas like cancer risk detection, novel therapeutics, personalized immunotherapy, and childhood cancers. The selection process involved over 100 scientific peer reviewers nationwide, emphasizing the scientific strengths and potential for translating research breakthroughs into life-saving treatments.

Curebound Awards $8.5 Million for Cancer Research, Aiming for Breakthroughs in Treatment

Curebound Awards $8.5 Million for Cancer Research, Aiming for Breakthroughs in Treatment

Curebound, a philanthropic organization dedicated to advancing cancer research, has announced the allocation of $8.5 million in grants to support 23 innovative cancer research projects. This funding includes a $1 million Cure Prize aimed at groundbreaking research with immediate clinical applications. The grants are distributed across various programs such as Catalyst, Discovery, Equity, Targeted Grants, and the Cure Prize, focusing on areas like cancer risk detection, novel therapeutics, personalized immunotherapy, and childhood cancers. The selection process involved over 100 scientific peer reviewers nationwide, emphasizing the projects' potential to translate research breakthroughs into life-saving treatments.

King Charles Announces Reduction in Cancer Treatment Due to Positive Response

King Charles Announces Reduction in Cancer Treatment Due to Positive Response

King Charles III has announced a significant milestone in his cancer treatment, revealing that due to early diagnosis and effective intervention, his treatment schedule will be reduced in the new year. This announcement was made in a video message broadcasted on Channel 4 as part of the Stand Up To Cancer campaign. The King, who was diagnosed with cancer in February 2024, has not disclosed the specific type of cancer but has been undergoing regular outpatient treatment. According to Buckingham Palace, the King has responded exceptionally well to the treatment, allowing doctors to move his care into a precautionary phase. Despite his diagnosis, King Charles has maintained a busy schedule, including state visits and public engagements, emphasizing the importance of early cancer detection and screening programs.

Oncostatin M's Role in Hematologic Malignancies Unveiled

Oncostatin M's Role in Hematologic Malignancies Unveiled

Recent research has identified Oncostatin M (OSM) as a significant factor in the progression of hematologic malignancies, such as myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML). The study reveals that STAT5-activating oncogenes induce OSM expression, which in turn affects bone marrow stromal cells through STAT3 phosphorylation. This interaction promotes a pro-inflammatory environment that supports disease progression. Elevated OSM levels have been observed in patients with MPN and AML, correlating with disease severity. The findings suggest that targeting the OSM signaling pathway could offer new therapeutic strategies for these malignancies.

Cancer Research Team Reports Promising Results in Glioblastoma Treatment Using Supplement Mix

Cancer Research Team Reports Promising Results in Glioblastoma Treatment Using Supplement Mix

Recent research led by Professor Indraneel Mittra at the Advanced Centre for Treatment, Research and Education in Cancer in Mumbai has revealed promising results in the treatment of glioblastoma, a highly aggressive brain cancer. The study involved administering a combination of resveratrol and copper to patients, which resulted in significant reductions in tumor aggressiveness and cancer biomarkers without any side effects. The approach challenges traditional cancer treatments that focus on attacking cancer cells, suggesting instead that healing tumors might be a viable strategy. The study enrolled ten patients who took the supplement mix before surgery, showing favorable shifts in key cancer markers compared to a control group.

Professor Mittra's Study Suggests New Approach to Brain Cancer Treatment

Professor Mittra's Study Suggests New Approach to Brain Cancer Treatment

Professor Indraneel Mittra from the Advanced Centre for Treatment, Research and Education in Cancer in Mumbai, India, has led a study exploring a novel approach to treating glioblastoma, a highly aggressive brain cancer. The study involved administering a combination of resveratrol and copper to patients, which appeared to support a healing process in tumors. This approach challenges the traditional methods of attacking cancer cells and suggests that healing tumors might be more effective. The study showed promising results, with treated tumors exhibiting less aggressive growth and reduced cancer markers.

Diakonos Oncology Secures $7 Million Grant to Advance Melanoma Therapy

Diakonos Oncology Secures $7 Million Grant to Advance Melanoma Therapy

Diakonos Oncology Corp., a biotechnology company based in Houston, has been awarded a significant research grant exceeding $7 million by the Cancer Prevention and Research Institute of Texas (CPRIT). This funding will support the advancement of their innovative therapy, DOC1021, into a Phase 1/2 clinical trial targeting refractory melanoma. DOC1021 is a first-in-class, patient-derived dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The therapy aims to address the unmet medical needs of patients with refractory melanoma, a form of skin cancer that no longer responds to standard treatments like immune checkpoint inhibitors. The grant positions Diakonos as one of only nine awardees from a competitive pool of 164 applicants.

BostonGene Unveils AI-Driven Breast Cancer Breakthroughs at SABCS 2025

BostonGene Unveils AI-Driven Breast Cancer Breakthroughs at SABCS 2025

BostonGene presented seven studies at the San Antonio Breast Cancer Symposium, showcasing its AI-driven platform's ability to uncover complex tumor biology and inform personalized treatment strategies. The research, conducted in collaboration with leading cancer centers, highlighted the platform's capability to identify predictive immune signatures, profile tumor microenvironments, and reveal novel therapeutic targets. These findings demonstrate the potential of BostonGene's technology to optimize breast cancer treatment and improve patient outcomes.

Fasting Enhances Breast Cancer Therapy Efficacy Through Glucocorticoid Activation

Fasting Enhances Breast Cancer Therapy Efficacy Through Glucocorticoid Activation

Recent research has shown that fasting can enhance the efficacy of breast cancer therapies by activating glucocorticoids. The study, conducted on mice, found that fasting reduced levels of insulin, IGF1, and leptin, which are factors that can promote tumor growth. By lowering these factors, fasting improved the effectiveness of breast cancer treatments, leading to reduced tumor size. The research highlights the potential of dietary interventions as a complementary approach to traditional cancer therapies. The study was conducted in accordance with ethical guidelines and involved various experimental models to assess the impact of fasting on tumor growth and treatment efficacy.

Lung Cancer Research Foundation Awards Grants for HER2-Driven Lung Cancer Projects

Lung Cancer Research Foundation Awards Grants for HER2-Driven Lung Cancer Projects

The Lung Cancer Research Foundation (LCRF), in collaboration with Boehringer Ingelheim, has awarded three early career investigators with two-year $250,000 grants. These awards are part of the 2025 LCRF | Boehringer Ingelheim Early Investigator Award, focusing on innovative approaches to treat HER2-mutated lung cancer. The projects aim to explore the science behind HER2 mutations as oncogenic drivers and develop novel therapeutic strategies for patients with these mutations. The recipients include Pinar Özden Eser from the Broad Institute of MIT and Harvard, Elizabeth Brunk from the University of North Carolina at Chapel Hill, and Paul Stockhammer from Yale University. These projects were selected through a rigorous review process by LCRF's Scientific Advisory Board.